Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 133-140

  Dilger, Karin ^a   Hohenester, Simon ^b   Winkler Budenhofer, Ursula ^c   Bastiaansen, Barbara A J ^b   Schaap, Frank G ^b   Rust, Christian ^c   Beuers, Ulrich ^b  

^a Dr Falk Pharma GmbH   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bile; Biotransformation; Cholestasis; Clinical trial; Drug transport

Indexed keywords

BILE ACID; BREAST CANCER RESISTANCE PROTEIN; CHENODEOXYCHOLIC ACID; GLYCOPROTEIN P; TAURINE; URSODEOXYCHOLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY TRACT DRAINAGE; CLINICAL ARTICLE; CONJUGATION; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFECT; DUODENOSCOPY; DUODENUM; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE PREPARATION; MORNING DOSAGE; PLASMA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UPREGULATION; WESTERN BLOTTING;

ADULT; BILE ACIDS AND SALTS; BILIARY TRACT; CARRIER PROTEINS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; CYTOCHROME P-450 CYP3A; DUODENUM; FEMALE; GENE EXPRESSION PROFILING; GLYCINE; HUMANS; INTESTINAL MUCOSA; LIVER CIRRHOSIS, BILIARY; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; TAURINE; URSODEOXYCHOLIC ACID;

EID: 84862663864     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.014     Document Type: Article

References (36)

1. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
2. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50:291-308.
3. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871-877.
4. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursode-oxycholic acid. Gastroenterology 2009;136:1281-1287.
5. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
6. Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105:2186-2194.
7. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3:318-328.
8. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36: 525-531.
9. Lindor KD, Lacerda MA, Jorgensen RA, et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 1998;93:1498-1504.
10. Crosignani A, Podda M, Battezzati PM, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991;14:1000-1007.
11. Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993;88:691-700.
12. Roda E, Azzaroli F, Nigro G, et al. Improved liver test and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 2002;34:523-527.
13. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003;38:203-209.
14. Pardi DS, Loftus Jr EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893.
15. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;22:783-788.
16. Hruz P, Zimmermann C, Gutmann H, et al. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006;55:395-402.
17. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009;156:7-27.
18. Beuers U, Kullak-Ublick GA, Pusl T, et al. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators? Clin Rev Allergy Immunol 2009;36:52-61.
19. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-485.
20. Guidance for Industry. Bioanalytical method validation. Food and Drug Administration. Available from: http://www.fda.gov/cder/guidance/4252fnl.pdf.
21. Van Hoogstraten HJ, De Smet MB, Renooij W, et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther 1998;12:965-971.
22. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972;13:201-206.
23. Medina JF, Martinez A, Vazquez JJ, et al. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997;25:12-17.
24. Prieto J, Garcia N, Marti-Climent JM, et al. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999;117:167-172.
25. Beuers U, Hohenester S, De Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010;52:1489-1496.
26. Rust C, Karnitz LM, Paya CV, et al. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 2000;275:20210-20216.
27. Hohenester S, Gates A, Wimmer R, et al. Phosphatidylinositol-3-kinase p110gamma contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J Hepatol 2010;53:918-926.
28. Rust C, Wild N, Bernt C, et al. Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem 2009;284:2908-2916.
29. Schulz S, Wimmer R, Zischka H, et al. Differential induction of mitochondrial failure by bile acids in a direct and Ca-independent fashion [abstract]. J Hepatol 2011;54:S280.
30. Hohenester S, de Buy Wenniger LJ, Paulusma CC, et al. A biliary HCO(3)(-) umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012;55:173-183.
31. Dilger K, Denk A, Heeg MH, et al. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 2005;41:595-602.
32. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40: 159-168.
33. Becquemont L, Glaeser H, Drescher S, et al. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther 2006;79:449-460.
34. Ni Z, Bikadi Z, Rosenberg MF, et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 2010;11:603-617.
35. Taipalensuu J, Törnblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164-170.
36. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007;453:643-659.